Calcitonin: What Is New In 1992

References

• Copp DH, Davidson AFG, Cheney BA. Evidence for a new parathyroid hormone which lowers blood calcium. Proc Canad Fed Biol Soc. 1961; 4: 17.
   Google Scholar
• Austin LA, Heath III H. Calcitonin. Physiology and pathophysiology. N Engl J Med. 1981; 304: 269–78.
   Google Scholar
• Tashjian AM, Wright DR, Ivey JL, Pont A. Calcitonin binding sites in bone: relationships to biological response and escape. Recent Prog Horm Res. 1978; 34: 285–334.
   Google Scholar
• Awbrey BJ, Rosenstein BD, Grubb SA, Talmage RV. The effect of chronic calcitonin deficiency after thyroidectomy on calcium regulating hormones and bone density in women. J Bone Joint Surg (Orthop Trans). 1985; 9: 229–30.
   Google Scholar
• Body JJ, Heath III H. Estimates of circulating monomelic calcitonin: physiological studies in normal and thyroidectomized man. J Clin Endocrinol Metab. 1983; 57: 897–903.
   Google Scholar
• Chambers TJ, Chambers JC, Symonds J, Darby JA. The effect of human calcitonin on the cytoplasmic spreading of rat osteoclasts. J Clin Endocrinol Metab. 1986; 63: 1080–85.
   Google Scholar
• Tiegs RD, Body JJ, Barta JM, Heath III H. Secretion and metabolism of monomelic human calcitonin: effects of age, sex, and thyroid damage. J Bone Miner Km. 1986; 1: 339–49.
   Google Scholar
• Tiegs RD, Body JJ, Wahner HW, Barta J, Riggs BL, Heath III H. Calcitonin secretion in postmenopausal osteoporosis. N Engl J Med. 1985; 312:1097-* 100.
   Google Scholar
• Sjoberg HE, Torring O, Granberg B, Ehrnsten U. Bucht E. Postmenopausal osteoporosis: response of immunoextracted calcitonin to a calcium clamp.’ Bone. 1989; 10: 15–8.
   Google Scholar
• Reginster JY, Deroisy R, Albert A et al Relationship between whole plasma calcitonin levels, calcitonin secretory capacity and plasma levels of estrone in healthy women and postmenopausal osteoporotics. J Clin Invest. 1989; 83:1 07377.
   Google Scholar
• Body JJ, Struelens M, Borkowski A, Mandart G Effects of estrogens and calcium on calcitonir secretion in postmenopausal women. J Clin Endo-i crinol Metab. 1989; 68:223–6.
   Google Scholar
• Body JJ, Demeester-Mirkine N, Borkowski A Suciu S, Corvilain J. Calcitonin deficiency in pri mary hypothyroidism. J Clin Endocrinol Metab’ 1986; 62: 700–3.
   Google Scholar
• Body JJ, Demeester-Mirkine N, Corvilain J Calcitonin deficiency after radioactive iodine treatment. Ann Intern Med. 1988; 109: 590–1.
   Google Scholar
• Demeester-Mirkine N, Bergmann P, Body JJ. Corvilain J. Calcitonin and bone mass status if congenital hypothyroidism. Calcif Tissue Int. 1990 46: 222–6.
   Google Scholar
• McDermott MT, Kidd GS. The role of calcitonir in the development and treatment of osteoporosis Endocrine Rev. 1987; 8: 377–90.
   Google Scholar
• Adlin EV, Maurer AH, Marks AD, Channick BJ Bone mineral density in postmenopausal womer treated with L-thyroxine./lm./Med. 1991; 90:360 6.
   Google Scholar
• Greenspan SL, Greenspan FS, Resnick NM, Blocl* JE, Friedlander AL, Genant HK. Skeletal integrity in premenopausal and postmenopausal womer receiving long-term L-thyroxine therapy. Am J Med. 1991;91:5–14.
   Google Scholar
• Lin HY, Harris TL, Flannery MS et al. Expression cloning of an adenylate cyclase-coupled calcitonir receptor. Science. 1991; 254: 1022–24.
   Google Scholar
• Body JJ, Glibert F, Nejai S, Fernandez G, Van Langendonck A, Borkowski A. Calcitonin receptors on circulating normal human lymphocytes. J Clin Endocrinol Metabol. 1990; 71: 675–81.
   Google Scholar
• Brunt LM, Wells SA Jr. Advances in the diagnosis and treatment of medullary thyroid carcinoma. Surg Clin North Am. 1987; 67: 263–79.
   Google Scholar
• Body JJ, Dumon JC, Sculier JPet al. Preliminary evaluation of calcitonin and PDN-21 as tumor markers for lung cancer. Henry Ford Med J. 1989; 37: 190–3.
   Google Scholar
• Zajac JD, Martin TJ, Hudson P, Niall H, Jacobs JW. Biosynthesis of calcitonin by human lung cancer cells. Endocrinology. 1985; I 16: 749–55.
   Google Scholar
• Malinen T, Palotie A, Pakkala S, Peltonen L, Ruutu T, Janson SE. Acceleration of chronic myeloid leukemia correlates with calcitonin gene hypermethylation. Blood. 1991; 77: 2435–40.
   Google Scholar
• Guilloteau D, Perdrisot R, Calmettes C et al. Diagno sis of medullary carcinoma of the thyroid (MCT) by calcitonin assay using monoclonal antibodies: criteriafor the pentagastrin stimulation test in hereditary MCT. J Clin Endocrinol Metab. 1990; 71: 1064–67.
   Google Scholar
• Body JJ, Heath III H. «Non-specific» elevations of plasma immunoreactive calcitonin in healthy individuals: discrimination from medullary thyroid carcinoma by a new extraction technique. Clin Chem. 1984;30:511–4.
   Google Scholar
• Overgaard K, Agnusdei D, Hansen MA, Maioli E, Christiansen C, Gennari C. Dose-response bioactivity and bioavailability of salmon calcitonin in premenopausal and postmenopausal women. J Clin Endocrinol Metab. 1991; 72: 344–9.
   Google Scholar
• Body JJ. Les hypercalcemies des tumeurs solides: physiopathologie et traitement. Rev Fr Endocrinol Clin, sous presse.
   Google Scholar
• Hosking DJ. Advances in the management of Paget’s disease of bone. Drugs. 1990; 40: 829–40.
   Google Scholar
• Ljunghall S, Gardsell P, Johnell O et al. Synthetic human calcitonin in postmenopausal osteoporosis: a placebo-controlled, double-blind study. Calcif Tissue Int. 1991; 49: 17–9.
   Google Scholar
• Overgaard K, Riis BJ, ChristiansenC, Podenphant J, Johansen JS. Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol. 1989; 30: 435–42.
   Google Scholar
• Reginster JY, Denis D, Albert A et al. I-year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet. 1987; ii: 1481–83.
   Google Scholar